Company Filing History:
Years Active: 2024-2025
Title: Marielle Martinez-Loi: Innovator in Ghrelin Agonist Research
Introduction
Marielle Martinez-Loi is a prominent inventor based in Biasca, Switzerland. She has made significant contributions to the field of pharmacology, particularly in the development of centrally-active ghrelin agonists. With a total of 2 patents to her name, her work is paving the way for new medical treatments.
Latest Patents
One of her latest patents is focused on a new compound, 3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-methyl-1-(1,3,3-trimethylpiperidin-4-yl)urea monohydrochloride salt. This compound has demonstrated a high capability to permeate through the blood-brain barrier and exhibit consistent ghrelin agonist activity at the central nervous system level. It is effective in treating and preventing medical conditions mediated by the ghrelin receptor in the central nervous system. Experimental tests have shown that the compound is highly effective in treating neurotoxic damage, providing a useful combined pattern of neuroprotective effects at both central and peripheral levels. Additionally, it is beneficial in treating conditions that require a reduction in heart rate, and it is pharmacologically active at low to moderate doses, indicating a favorable therapeutic index.
Career Highlights
Marielle Martinez-Loi is currently associated with Helsinn Healthcare SA, where she continues her innovative research. Her work is characterized by a commitment to advancing medical science and improving patient outcomes through her discoveries.
Collaborations
She collaborates with notable colleagues, including Claudio Giuliano and Claudio Pietra, who contribute to her research endeavors.
Conclusion
Marielle Martinez-Loi is a trailblazer in the field of pharmacology, with her innovative work on ghrelin agonists promising to enhance treatment options for various medical conditions. Her contributions are vital to the ongoing advancement of medical science.